BLOG

Robust Medical's 2020 net profit is expected to increase by 568%-623%, and domestic and overseas sales of medical protective equipment have increased significantly

Category： Company News

Time： 2021-06-02

Summary： On January 12, Winner Medical (300888) announced the 2020 annual performance forecast. The company expects its operating income in 2020 to be 11.5 billion-13.5 billion yuan, a year-on-year increase of 151%-195%

On January 12, Winner Medical (300888) announced the 2020 annual performance forecast. The company expects its operating income in 2020 to be 11.5 billion-13.5 billion yuan, a year-on-year increase of 151%-195%; the net profit for 2020 is expected to be 36.5 RMB -39.5 billion, a year-on-year increase of 568% -623%.

For Prudent Medical, which has just landed on the capital market in September 2020, this performance will also become the company's first annual "transcript" after its listing. According to the announcement, the company's substantial annual increase is mainly due to two reasons.

On the one hand, during the outbreak of the new crown pneumonia, the company responded quickly and worked overtime to produce anti-epidemic products, and related medical protective equipment (mainly masks, protective clothing, isolation gowns, etc.) online and offline channels, domestic and overseas market sales were substantial improve.

On the other hand, the company has widely used the self-developed cotton spunlace non-woven materials in surgical gowns, isolation gowns, protective clothing, masks and other products, which not only solves the shortage of raw materials, but also enjoys the advantages of comfort and other advantages by customers. Highly recognized. The self-developed raw materials have been produced on a large scale, which has reduced product costs and further effectively improved the annual performance.

According to the third quarter report of 2020 disclosed by Wenjian Medical, the company achieved a net profit of 3.15 billion yuan in the first three quarters, a year-on-year increase of 678.64%. Based on this calculation, the company's fourth-quarter net profit is expected to be 500 million to 800 million yuan, compared with 142 million yuan for the same period last year (2019).

After the 2020 performance forecast was released, Huachuang Securities released a research report and maintained its strong recommendation rating for stable medical care. Huachuang Securities believes that the epidemic has catalyzed the rapid growth of the company's medical business, and its revenue is in line with expectations. At the same time, the national level put forward a reserve plan, the epidemic has raised residents’ awareness of protection, masks may become normalized and necessary temporary protective equipment, the company’s medical business overseas customers, domestic hospitals and pharmacies have expanded channels, and the future medical business growth rate may be normal.化 Improve.

Huachuang Securities also pointed out that the online channels of the company's consumer goods business has rapidly increased in the cotton era, and private domain traffic operations such as small programs have performed well, and the number of members has increased significantly. In terms of offline channels, in the second half of the year, the company's offline expansion stores resumed to accelerate expansion and sinking. The new brand Jinliang's life layout was steadily advancing, and the mid- to long-term consumer goods business may become the main source of revenue contribution.

According to the information from Tianyan Check, Wenjian Medical was established in 1995 and was mainly engaged in the production and sales of medical dressings at the beginning of its establishment. After years of development, the company has gradually changed from OEM OEM to independent brand and OEM OEM, and from foreign markets to domestic and foreign markets. From single product sales to providing comprehensive wound care solutions, the company has become the domestic medical dressing industry. Leading enterprises.

In the whole year of 2020, the prevention and control of the new crown epidemic will undoubtedly bring a significant boost to the performance of the cotton era. However, with the gradual improvement of the epidemic prevention and control situation, on the basis of the "high base" of 2020 performance, how to maintain the growth of the performance of Steady Medical in the next year seems to pose a certain challenge.

It is worth mentioning that in December 2020, Winner Medical launched an equity incentive plan. It intends to grant restricted stock incentive plans to no more than 1053 objects of the company. The planned number of shares to be granted is 6.5 million shares, accounting for approximately the company's total. 1.52% of share capital

In this equity incentive plan, Winner Medical also gives the evaluation goals for future performance. The goals are divided into two levels, corresponding to the ownership ratio of 80% and 100% of the stocks. The corresponding income targets for the two levels in 2021 are not low. At 10 billion yuan and 12 billion yuan, the corresponding revenue targets for these two tiers in 2022 are not less than 20% and 30% relative to 2021 revenue growth.

Cai Xin, the chief analyst of Southwest Securities' Home Life, believes that if the target of part of the sales restriction in the 2021 incentive plan of Prudent Medical is reached, the company’s average annual compound growth rate from 2019 to 2021 is about 47.9%, and the assessment target is high, which shows that the company is in Confidence in maintaining rapid income growth in the post-epidemic period.

Jiang Han, a senior researcher at Pangu Think Tank, also pointed out that the medical business of Prudent Medical has become a key supplier of epidemic prevention materials for the government and many hospitals in China, and it has also achieved effective development of new customers overseas, and still faces good development prospects in the future. In the cotton era and other healthy consumer sectors, in a sense, it is the integration of the industrial chain. Its main health concept has a unique market advantage and will become the second curve of the company's performance growth.

Keywords： Robust Medical's 2020 net profit is expected to increase by 568%-623%, and domestic and overseas sales of medical protective equipment have increased significantly

Related Blog

Knowledge

Recent Show

Company News

Industry News

PREV： 2021 Shanghai International Medical Protective Products Exhibition will be held in the Expo Exhibition Hall

NEXT： 2021 China Changchun Dental Equipment and Dental Materials Expo will be held on May 21

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home

Product Search

Your Expert Robin Engine Supplier

SEARCH
%{tishi_zhanwei}%